Team-based Implementation of Hypertension Management in Childhood Lupus (ABOUT TIME)
tiistai 25. elokuuta 2026 päivittänyt: Joyce Chang, Boston Children's Hospital
Comparing Implementation Strategies to Advance Cardiovascular Health in Children With Lupus
The goal of this study is to compare the effectiveness of widely used implementation strategies to promote adherence to guideline-concordant evidence-based practices for monitoring and controlling blood pressure in patients with lupus who are in pediatric care.
A total of 16 pediatric lupus care teams will be randomly assigned one or more of these implementation strategies.
The investigators will determine which strategy is better at ensuring the evidence-based practices reach all patients as intended and concurrently gather additional information about health outcomes as they pertain to children with childhood-onset lupus.
Tutkimuksen yleiskatsaus
Tila
Ei vielä rekrytointia
Opintotyyppi
Interventio
Ilmoittautuminen (Arvioitu)
1200
Vaihe
- Ei sovellettavissa
Osallistumiskriteerit
Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.
Kelpoisuusvaatimukset
Opintokelpoiset iät
- Lapsi
- Aikuinen
- Vanhempi Aikuinen
Hyväksyy terveitä vapaaehtoisia
Ei
Kuvaus
Inclusion Criteria for EHR Data Collection:
- ICD-10-CM or SNOMED-CT diagnosis code for SLE
- Completed a pediatric rheumatology outpatient clinical visit at a participating implementation site within 12 months of each data collection timepoint
Inclusion Criteria for the Patient Survey Group:
- Diagnosis of childhood-onset Systemic Lupus Erythematosus (cSLE)
- Must have had a pediatric rheumatology clinical visit at a participating implementation site within 12 months of each data collection timepoint
- Age 12 years or older at enrollment
Inclusion Criteria for the Caregiver Survey Group:
- Individuals at least 18 years of age
- Parent or guardian of a child with cSLE who is followed by a care team at a participating site
Inclusion Criteria for the Lupus Care Team Member Survey Group:
- Individuals at least 18 years of age
- Health care team members within a pediatric subspecialty that manages patients with cSLE at a participating site
Inclusion Criteria for the Patient Interview Group:
- Diagnosis of childhood-onset Systemic Lupus Erythematosus (cSLE)
- Completed a clinical visit in the participating site's outpatient rheumatology clinic within the 12 months prior to enrollment
- Age 12 years or older at enrollment
- Able to provide verbal assent if below age 18 years of age or verbal consent if age 18 years and older. For minors, verbal parental/guardian permission (informed consent) is required.
- Have access to a device with audio or audiovisual conferencing capabilities
Inclusion Criteria for the Caregiver Interview Group:
- Individuals 18 years old or older at enrollment
- Parent or guardian of a child with cSLE who is followed by a care team at a participating pediatric rheumatology site and has completed a clinical visit within the 12 months prior to enrollment
- Able to provide verbal informed consent prior to the interview
- Have access to a device with audio or audiovisual conferencing capabilities
Inclusion Criteria for the Lupus Care Team Member Interview Group:
- Individuals ages 18 years of age or older at enrollment
- Health care team members that are in a pediatric subspecialty clinic that manages patients with cSLE at a participating site
- Able to provide verbal informed consent prior to the interview
- Have access to a device with audio or audiovisual conferencing capabilities
Exclusion Criteria for all Interview Groups:
- Unable or without cognitive capacity to participate in an interview, as determined by the investigator(s).
- No prospective interview participants will be excluded on the basis of sex, race, ethnicity, or language preference.
Opintosuunnitelma
Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Muut
- Jako: Satunnaistettu
- Inventiomalli: Tehtävätehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Active Comparator: Health Navigator without a Pre-Visit Worksheet
Adding only the health navigator engagement intervention
|
Adding a health navigator to the healthcare team to improve coordination among providers from different specialties and work closely with patients and their families.
The health navigator acts as a bridge between families and the care team by helping facilitate care coordination, ensuring patient and family voices are heard, and explaining medical information in clear language.
They also assist families with keeping track of medical appointments, connecting to local community resources, and providing extra support throughout the care process.
|
|
Active Comparator: Team Charter with Performance Monitoring without a Pre-Visit Worksheet
Adding only the team charter with performance monitoring intervention.
|
Care teams will work together to build clear plans that explain everyone's goals, roles, and daily responsibilities.
The team will regularly check its performance data to see what is working well and what needs improvement.
By making small, step-by-step changes over time, the team can continuously refine its approach until it reaches its goals.
|
|
Active Comparator: Health Navigator with a Pre-Visit Worksheet
Adding both the health navigator engagement and pre-visit worksheet interventions
|
Adding a health navigator to the healthcare team to improve coordination among providers from different specialties and work closely with patients and their families.
The health navigator acts as a bridge between families and the care team by helping facilitate care coordination, ensuring patient and family voices are heard, and explaining medical information in clear language.
They also assist families with keeping track of medical appointments, connecting to local community resources, and providing extra support throughout the care process.
Care teams will give patients and families a short worksheet to fill out before their appointment.
This form helps them prepare to talk with their doctor about high blood pressure and heart disease risk.
It helps patients and caregivers feel ready to ask questions and take an active role in planning their heart health care.
|
|
Active Comparator: Team Charter and Performance Monitoring with a Pre-Visit Worksheet
Adding both the team charter and performance monitoring and pre-visit worksheet interventions.
|
Adding a health navigator to the healthcare team to improve coordination among providers from different specialties and work closely with patients and their families.
The health navigator acts as a bridge between families and the care team by helping facilitate care coordination, ensuring patient and family voices are heard, and explaining medical information in clear language.
They also assist families with keeping track of medical appointments, connecting to local community resources, and providing extra support throughout the care process.
Care teams will give patients and families a short worksheet to fill out before their appointment.
This form helps them prepare to talk with their doctor about high blood pressure and heart disease risk.
It helps patients and caregivers feel ready to ask questions and take an active role in planning their heart health care.
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Representative Reach of the Implementation Strategies
Aikaikkuna: Evaluated at months 0, 6, 9, and then every 3 months through month 18.
|
The absolute difference in proportion of cSLE patients living in areas with low/very low child opportunity that receive evidence-based intervention components (ABPM and RAS inhibitors) vs. those living in areas with high/very high opportunity.
Child opportunity, defined as neighborhood resources and conditions that support healthy childhood development, will be measured by linking FIPS codes to the Child Opportunity Index (COI) version 3.0, a multidimensional area-level composite of 44 indicators in domains of education, physical environment and economic conditions, and categorized according to national rank.
|
Evaluated at months 0, 6, 9, and then every 3 months through month 18.
|
|
Fidelity: The extent to which the hypertension evaluation and management interventions are delivered as intended.
Aikaikkuna: Evaluated at months 0, 6, 9, and then every 3 months through month 18.
|
The pre-post intervention change in proportion of cSLE patients that receive core components of the hypertension evaluation and management interventions.
1) Adherence to hypertension evaluation will be measured by change in the % of SLE patients with LN or elevated BP who have an ABPM procedure code within the last year.
Elevated BP will be defined according to AAP/AHA guidelines: ≥120/80 if age ≥13 years; ≥90th%ile or 120/80 (whichever is lower) if age <13 years,17 on 2 or more occasions.
2) Adherence to pharmacologic treatment will be change in % of SLE patients with LN or elevated BP who are prescribed RAS inhibitors.
|
Evaluated at months 0, 6, 9, and then every 3 months through month 18.
|
|
Improvement in Blood Pressure Control
Aikaikkuna: Evaluated at months 0, 6, 9, and then every 3 months through month 18.
|
The change in percentage of SLE patients that achieve target clinic BP (<130/80 if age 13 years or older; lower of <130/80 or <90th%ile if age <13) using the average of the last two clinic SBP or DBP readings on separate days for each patient (oscillometric or auscultory).
If ≥1 BP reading is taken on a single day, the daily mean will be used.
|
Evaluated at months 0, 6, 9, and then every 3 months through month 18.
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Fidelity to Dietary Sodium Counseling
Aikaikkuna: Evaluated at months 0, 18, and 30.
|
The change in % of sampled patients with elevated blood pressure that report having discussed dietary sodium reduction with their care team.
|
Evaluated at months 0, 18, and 30.
|
|
Maintenance of Intervention Fidelity
Aikaikkuna: Months 18-42
|
The change in adherence to the hypertension evaluation and management intervention at each site between month 18 and month 42.
Adherence is defined by the % of SLE patients with lupus nephritis (LN) or elevated blood pressure who have an ABPM procedure code within the last year, and the % of SLE patients with LN or elevated BP who are prescribed RAS inhibitors.
|
Months 18-42
|
|
Maintenance of Intervention Reach
Aikaikkuna: Months 18-42
|
The change in % of SLE patients who receive ambulatory blood pressure monitoring (ABPM) and renin-angiotensin system (RAS) inhibition in low/very low vs. high/very high COI between months 18 and 42.
|
Months 18-42
|
|
Maintenance of Blood Pressure Control
Aikaikkuna: Months 18-42
|
The change in proportion of SLE patients that maintain their target average clinic blood pressure, defined as <130/80 if age 13 years or older; lower of <130/80 or <90th%ile if age <13, between months 18 and 42.
|
Months 18-42
|
|
24-hour Ambulatory Blood Pressure Control among Patients with Lupus Nephritis
Aikaikkuna: Evaluated at months 0, 6, 9, and then every 3 months through month 18.
|
Based on their most recent ABPM study, defined as the change in % of patients with a most recent 24-hour mean arterial pressure (MAP) of <125/75 if age 13 years and older or the lower of <125/75 or 90th%ile if age <13 years old.
|
Evaluated at months 0, 6, 9, and then every 3 months through month 18.
|
Yhteistyökumppanit ja tutkijat
Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.
Sponsori
Yhteistyökumppanit
Opintojen ennätyspäivät
Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan julkisella verkkosivustolla.
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Arvioitu)
Torstai 1. huhtikuuta 2027
Ensisijainen valmistuminen (Arvioitu)
Torstai 30. marraskuuta 2028
Opintojen valmistuminen (Arvioitu)
Lauantai 30. marraskuuta 2030
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Perjantai 21. elokuuta 2026
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Tiistai 25. elokuuta 2026
Ensimmäinen Lähetetty (Todellinen)
Perjantai 28. elokuuta 2026
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Perjantai 28. elokuuta 2026
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Tiistai 25. elokuuta 2026
Viimeksi vahvistettu
Lauantai 1. elokuuta 2026
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muut tutkimustunnusnumerot
- P00054342
- BPS-2025C1-43826 (Muu apuraha/rahoitusnumero: Patient-Centered Outcomes Research Institute)
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Ei
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Ei
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .